Verve Therapeutics Stock Forecast, Price & News

+5.35 (+8.29 %)
(As of 09/16/2021 12:00 AM ET)
Today's Range
50-Day Range
52-Week Range
Volume538,405 shs
Average Volume420,156 shs
Market Capitalization$3.35 billion
P/E RatioN/A
Dividend YieldN/A
30 days | 90 days | 365 days | Advanced Chart
Receive VERV News and Ratings via Email

Sign-up to receive the latest news and ratings for Verve Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

About Verve Therapeutics

Verve Therapeutics, Inc., a genetic medicines company, engages in developing gene editing medicines for patients to treat cardiovascular diseases. Its lead product candidate is VERVE-101, a single-course gene editing treatment that permanently turns off the PCSK9 gene in the liver. The company also engages in the development ANGPTL3 program to permanently turn off the ANGPTL3 gene in the liver. It has a collaboration and license agreement with Beam Therapeutics; a development and option agreement with Acuitas Therapeutics, Inc.; and a Cas9 license agreement with The Broad Institute and the President and Fellows of Harvard College. The company was formerly known as Endcadia, Inc. and changed its name to Verve Therapeutics, Inc. in January 2019. Verve Therapeutics, Inc. was incorporated in 2018 and is based in Cambridge, Massachusetts.


Verve Therapeutics (NASDAQ:VERV) Shares Gap Up to $64.52
Verve Therapeutics (NASDAQ:VERV) Shares Gap Up to $64.52
September 16, 2021 |
Cathie Wood Bets Big on These 2 “Strong Buy” Stocks
Cathie Wood Bets Big on These 2 “Strong Buy” Stocks
September 15, 2021 |
Verve Therapeutics (NASDAQ:VERV) Stock Price Down 8.2%
Verve Therapeutics (NASDAQ:VERV) Stock Price Down 8.2%
September 13, 2021 |
Verve Therapeutics (NASDAQ:VERV) Shares Gap Up to $70.07
Verve Therapeutics (NASDAQ:VERV) Shares Gap Up to $70.07
September 9, 2021 |
Verve Therapeutics (NASDAQ:VERV) Reaches New 1-Year High at $77.73
Verve Therapeutics (NASDAQ:VERV) Reaches New 1-Year High at $77.73
September 7, 2021 |
Verve Therapeutics (NASDAQ:VERV) Hits New 52-Week High at $74.44
Verve Therapeutics (NASDAQ:VERV) Hits New 52-Week High at $74.44
August 30, 2021 |
Verve Therapeutics (NASDAQ:VERV) Stock Price Up 6.3%
Verve Therapeutics (NASDAQ:VERV) Stock Price Up 6.3%
August 26, 2021 |
Verve Therapeutics (NASDAQ:VERV) Shares Gap Down to $63.44
Verve Therapeutics (NASDAQ:VERV) Shares Gap Down to $63.44
August 25, 2021 |
See More Headlines

Industry, Sector and Symbol

Sales & Book Value






Overall MarketRank

1.44 out of 5 stars

Medical Sector

948th out of 1,352 stocks

Pharmaceutical Preparations Industry

464th out of 665 stocks

Analyst Opinion: 1.4Community Rank: 5.0Dividend Strength: 0.0Insider Behavior: 0.8Valuation: 0.0 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles

Verve Therapeutics (NASDAQ:VERV) Frequently Asked Questions

Is Verve Therapeutics a buy right now?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Verve Therapeutics in the last twelve months. There are currently 1 hold rating and 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" Verve Therapeutics stock.
View analyst ratings for Verve Therapeutics
or view top-rated stocks.

What stocks does MarketBeat like better than Verve Therapeutics?

Wall Street analysts have given Verve Therapeutics a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Verve Therapeutics wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

When is Verve Therapeutics' next earnings date?

Verve Therapeutics is scheduled to release its next quarterly earnings announcement on Thursday, November 11th 2021.
View our earnings forecast for Verve Therapeutics

How were Verve Therapeutics' earnings last quarter?

Verve Therapeutics, Inc. (NASDAQ:VERV) announced its earnings results on Thursday, August, 12th. The company reported ($2.13) earnings per share (EPS) for the quarter, missing the Thomson Reuters' consensus estimate of ($0.53) by $1.60.
View Verve Therapeutics' earnings history

What price target have analysts set for VERV?

4 Wall Street analysts have issued 1 year price targets for Verve Therapeutics' stock. Their forecasts range from $50.00 to $92.00. On average, they expect Verve Therapeutics' stock price to reach $74.50 in the next year. This suggests a possible upside of 6.6% from the stock's current price.
View analysts' price targets for Verve Therapeutics
or view top-rated stocks among Wall Street analysts.

Who are Verve Therapeutics' key executives?

Verve Therapeutics' management team includes the following people:
  • Dr. Burt A. Adelman M.D., Co-Founder & Independent Chairman (Age 69, Pay $60k)
  • Dr. Sekar Kathiresan, Co-Founder, CEO & Director (Age 49, Pay $721.99k)
  • Mr. Andrew D. Ashe J.D., Pres & COO (Age 54, Pay $532.69k)
  • Dr. Anthony Philippakis Ph.D., M.D., Co-Founder
  • Dr. Andrew Bellinger, Chief Scientific Officer (Age 43, Pay $487.59k)
  • Dr. Kiran Musunuru M.P.H., M.D., Ph.D., Co-Founder & Sr. Scientific Advisor
  • Dr. J. Keith Joung, Co-Founder
  • Dr. Barry S. Ticho FACC, M.D., Ph.D., Co-Founder (Age 61)
  • Mr. Issi Rozen, Co-Founder & Strategic Advisor
  • Ms. Margaret Beaudoin, VP of Fin. (Age 52)

Who are some of Verve Therapeutics' key competitors?

When did Verve Therapeutics IPO?

(VERV) raised $201 million in an initial public offering (IPO) on Thursday, June 17th 2021. The company issued 11,800,000 shares at a price of $16.00-$18.00 per share. J.P. Morgan, Jefferies, Guggenheim Securities and William Blair acted as the underwriters for the IPO.

What is Verve Therapeutics' stock symbol?

Verve Therapeutics trades on the NASDAQ under the ticker symbol "VERV."

When did the company's quiet period expire?

Verve Therapeutics' quiet period expired on Tuesday, July 27th. Verve Therapeutics had issued 14,035,789 shares in its public offering on June 17th. The total size of the offering was $266,679,991 based on an initial share price of $19.00. During the company's quiet period, underwriters and any insiders involved in the IPO were prevented from issuing any earnings forecasts or research reports for the company because of regulations issued by the Securities and Exchange Commission. Now that the company's quiet period has ended, brokerages that served as underwriters are now able to initiate research on the company.

Who are Verve Therapeutics' major shareholders?

Verve Therapeutics' stock is owned by many different retail and institutional investors. Top institutional shareholders include FMR LLC (7.48%), Redmile Group LLC (4.20%), JPMorgan Chase & Co. (2.00%), RA Capital Management L.P. (1.91%), Citadel Advisors LLC (1.80%) and Logos Global Management LP (1.64%). Company insiders that own Verve Therapeutics stock include Cormorant Asset Management, Lp and Logos Global Management Lp.

Which major investors are buying Verve Therapeutics stock?

VERV stock was acquired by a variety of institutional investors in the last quarter, including FMR LLC, Redmile Group LLC, JPMorgan Chase & Co., RA Capital Management L.P., Citadel Advisors LLC, Logos Global Management LP, Price T Rowe Associates Inc. MD, and ARK Investment Management LLC. Company insiders that have bought Verve Therapeutics stock in the last two years include Cormorant Asset Management, Lp, and Logos Global Management Lp.

How do I buy shares of Verve Therapeutics?

Shares of VERV can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Verve Therapeutics' stock price today?

One share of VERV stock can currently be purchased for approximately $69.87.

How much money does Verve Therapeutics make?

Verve Therapeutics has a market capitalization of $3.35 billion.

How many employees does Verve Therapeutics have?

Verve Therapeutics employs 63 workers across the globe.

What is Verve Therapeutics' official website?

The official website for Verve Therapeutics is

How can I contact Verve Therapeutics?

The company can be reached via phone at 978-501-3026 or via email at [email protected]

This page was last updated on 9/16/2021 by Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.